RedHill Biopharma (RDHL) Net Equity Issued and Repurchased (2013 - 2022)

RedHill Biopharma (RDHL) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $7.6 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Net Equity Issued and Repurchased fell 61.74% year-over-year to $7.6 million; the TTM figure through Dec 2022 stood at $23.8 million (down 69.69% YoY), while the FY2025 annual figure was $7.8 million, down 6.04% from the prior year.
• Net Equity Issued and Repurchased fell to $7.6 million in Q4 2022 per RDHL's latest filing, from $15.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $57.9 million in Q1 2021 and bottomed at $273000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $14.0 million across 4 years, with a median of $8.8 million in 2020.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 5580.59% in 2022 and fell as far as 98.77% in 2022.
• RedHill Biopharma's Net Equity Issued and Repurchased stood at $18.3 million in 2018, then plunged by 54.4% to $8.4 million in 2020, then surged by 136.92% to $19.8 million in 2021, then plunged by 61.74% to $7.6 million in 2022.
• Business Quant data shows RDHL's Net Equity Issued and Repurchased at $7.6 million in Q4 2022, $15.5 million in Q2 2022, and $713000.0 in Q1 2022.